NLS Pharmaceutics AG has announced a significant update to its merger and reorganization plans with Kadimastem Ltd. The two companies have entered into a Fifth Amendment to their Agreement of Merger and Plan of Reorganization. This amendment, effective as of July 1, 2025, involves NLS Pharmaceutics Ltd., its Israeli subsidiary NLS Pharmaceuticals (Israel) Ltd., and Kadimastem Ltd., an Israeli publicly traded company. The amendment outlines further commitments to carry out the merger provisions and signifies continued progress towards the planned reorganization. The companies involved have expressed their commitment to executing the necessary documents and actions to fulfill the amendment's provisions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.